Protagonist Therapeutics (PTGX) Competitors $75.73 -1.95 (-2.51%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$75.68 -0.05 (-0.06%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, and ELANShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), Qiagen (QGEN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna Qiagen Elanco Animal Health Genmab A/S (NASDAQ:GMAB) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership. Is GMAB or PTGX more profitable? Genmab A/S has a net margin of 37.53% compared to Protagonist Therapeutics' net margin of 24.88%. Genmab A/S's return on equity of 21.03% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Protagonist Therapeutics 24.88%8.12%7.41% Do analysts rate GMAB or PTGX? Genmab A/S presently has a consensus price target of $40.80, suggesting a potential upside of 24.58%. Protagonist Therapeutics has a consensus price target of $72.00, suggesting a potential downside of 4.93%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82Protagonist Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more risk & volatility, GMAB or PTGX? Genmab A/S has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Does the media favor GMAB or PTGX? In the previous week, Genmab A/S had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 28 mentions for Genmab A/S and 22 mentions for Protagonist Therapeutics. Genmab A/S's average media sentiment score of 0.66 beat Protagonist Therapeutics' score of 0.48 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of GMAB or PTGX? 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, GMAB or PTGX? Genmab A/S has higher revenue and earnings than Protagonist Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B6.73$1.14B$1.9916.46Protagonist Therapeutics$434.43M10.84$275.19M$0.70108.19 SummaryGenmab A/S beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.83B$3.41B$6.08B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E Ratio108.1923.0784.6627.19Price / Sales10.84486.15608.04132.91Price / Cash17.2046.9737.8662.13Price / Book6.6810.5012.386.65Net Income$275.19M-$52.47M$3.32B$276.79M7 Day Performance-12.95%2.90%2.25%1.75%1 Month Performance27.88%15.36%9.63%5.15%1 Year Performance61.06%14.29%73.84%36.96% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics1.7685 of 5 stars$75.73-2.5%$72.00-4.9%+61.2%$4.83B$434.43M108.19120Analyst ForecastInsider TradeGMABGenmab A/S3.7565 of 5 stars$31.81-0.1%$40.80+28.3%+44.9%$20.42B$3.26B15.982,682Trending NewsAnalyst ForecastShort Interest ↑Analyst RevisionSMMTSummit Therapeutics3.0162 of 5 stars$21.35-5.7%$31.29+46.5%-6.4%$15.86B$700K-21.14110Upcoming EarningsASNDAscendis Pharma A/S2.8766 of 5 stars$209.55-2.4%$244.64+16.7%+58.9%$12.93B$393.54M-40.611,017News CoverageAnalyst RevisionGap UpRDYDr. Reddy's Laboratories3.1513 of 5 stars$14.34+1.2%$16.95+18.2%-10.1%$11.97B$3.81B21.7327,811Positive NewsVTRSViatris3.1067 of 5 stars$9.74-2.5%$10.40+6.8%-14.6%$11.36B$14.12B-3.3632,000News CoverageAnalyst ForecastROIVRoivant Sciences3.0735 of 5 stars$16.04-0.5%$19.94+24.3%+42.9%$10.95B$29.05M-22.91860Insider TradeBBIOBridgeBio Pharma4.494 of 5 stars$55.49+1.3%$63.94+15.2%+108.9%$10.61B$235.81M-13.57400Positive NewsAnalyst RevisionMRNAModerna4.2459 of 5 stars$26.83-2.5%$41.81+55.8%-52.8%$10.48B$3.06B-3.565,800Analyst RevisionQGENQiagen4.1288 of 5 stars$46.93flat$49.40+5.3%+14.5%$10.43B$2.04B27.735,765ELANElanco Animal Health2.5478 of 5 stars$19.77-1.5%$19.14-3.2%+54.6%$9.82B$4.48B22.999,000Analyst Revision Related Companies and Tools Related Companies Genmab A/S Alternatives Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Viatris Alternatives Roivant Sciences Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Qiagen Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
